P2Y12 Receptor Protein
Pathway Diagram
Mermaid diagram (expand to render)
Introduction
P2Y12 Receptor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#f0f0f0; text-align:center;">Purinergic Receptor P2Y12</th></tr>
<tr><td><b>Gene Symbol</b></td><td>[P2RY12](/genes/p2ry12)</td></tr>
<tr><td><b>UniProt ID</b></td><td>[Q9H0Y9](https://www.uniprot.org/uniprotkb/Q9H0Y9/entry)</td></tr>
<tr><td><b>Subcellular Localization</b></td><td>Plasma Membrane, Microglial Processes</td></tr>
<tr><td><b>Protein Family</b></td><td>P2Y Receptor Family (GPCR)</td></tr>
<tr><td><b>Molecular Weight</b></td><td>~39 kDa</td></tr>
<tr><td><b>Ligands</b></td><td>ADP (agonist), Ticagrelor, Clopidogrel (antagonists)</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/ami" style="color:#ef9a9a">AMI</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-f99ce4ca" style="color:#ce93d8" title="Score: 0.50">Purinergic P2Y12 Inverse Agonist Therapy...</a><br><a href="/hypothesis/h-5daecb6e" style="color:#ce93d8" title="Score: 0.46">Microglial Purinergic Reprogramming...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">277 edges</a></td>
</tr>
</table>
</div>
Overview
P2Y12 Receptor is a Gi/o protein-coupled receptor encoded by the [P2RY12](/proteins/p2ry12-protein) gene that plays critical roles in microglial function, platelet activation, and neuroimmune signaling.[^1] Unlike most P2Y receptors, P2Y12 is uniquely expressed in [microglia](/cell-types/microglia-neuroinflammation) in the central nervous system, making it a key marker for surveying microglia and a potential therapeutic target for neurodegenerative diseases.[^2]
Structure
P2Y12R is a typical GPCR with seven transmembrane domains:
- N-terminal extracellular domain: Contains disulfide bonds and ligand-binding site
- Transmembrane helices (TM1-TM7): Form the ligand-binding pocket
- Intracellular loops: Couple to Gi/o proteins
- C-terminal tail: Contains serine/threonine phosphorylation sites
The receptor binds ADP through a binding pocket formed by transmembrane domains, with species-specific pharmacological profiles.[^3]
Normal Function
Microglial Surveillance
P2Y12R is highly enriched in homeostatic microglia and regulates:
- Process motility: Extension and retraction of microglial processes in response to ATP/ADP signals
- Surveying behavior: Continuous scanning of the neuronal environment
- Damage sensing: Rapid detection of cellular injury via extracellular nucleotide release
Platelet Activation
In platelets, P2Y12R mediates:
- ADP-induced platelet aggregation: Critical secondary agonist response
- Thrombus stabilization: Prevents disaggregation
- Cross-talk with other agonists: Amplifies responses to collagen and thrombin
Purinergic Signaling
P2Y12R participates in the purinergic signaling cascade:
ATP release: From damaged cells or active [neurons](/entities/neurons)
ATP hydrolysis: ECD converts ATP to ADP
P2Y12 activation: ADP binds and activates Gi/o signaling
Cellular responses: Microglial process extension or platelet aggregationRole in Neurodegeneration
Alzheimer's Disease
P2Y12R in AD exhibits complex, context-dependent roles:[^4]
- Early disease: P2Y12R+ microglia may limit amyloid-β plaque formation
- Disease progression: Loss of P2Y12R expression correlates with disease severity
- Therapeutic potential: P2Y12R modulators may enhance microglial plaque clearance
- Genetic association: P2RY12 variants linked to AD risk in GWAS studies
Parkinson's Disease
- Dopaminergic neuron protection: P2Y12R regulates microglial responses to [α-synuclein](/proteins/alpha-synuclein)
- Neuroinflammation: Modulates cytokine release in response to dopaminergic degeneration
- Therapeutic targeting: P2Y12 antagonists may reduce excessive microglial activation
Amyotrophic Lateral Sclerosis (ALS)
- Microglial activation: P2Y12R+ microglia show altered responses in ALS models
- Disease progression: Loss of P2Y12R correlates with disease progression
- Therapeutic potential: Targeting P2Y12 signaling may modulate neuroinflammation
Multiple Sclerosis
- Demyelination: P2Y12R regulates oligodendrocyte precursor cell responses
- Remyelination: Modulates OPC differentiation and repair
- Therapeutic targeting: P2Y12 modulators may enhance remyelination
Therapeutic Targeting
Drug Development
| Agent | Type | Status | Indication |
|-------|------|--------|------------|
| Ticagrelor | Reversible antagonist | Approved (cardiology) | Antiplatelet |
| Clopidogrel | Irreversible antagonist | Approved (cardiology) | Antiplatelet |
| Prasugrel | Irreversible antagonist | Approved (cardiology) | Antiplatelet |
| Experimental | Agonist | Preclinical | Neuroprotection |
CNS Drug Development Challenges
- [Blood-brain barrier](/entities/blood-brain-barrier) penetration: Most P2Y12R drugs don't cross into CNS
- Peripheral effects: Platelet inhibition causes bleeding risk
- [Microglia](/entities/microglia)-selectivity: Need CNS-targeted compounds
- Temporal targeting: Different strategies for early vs. late disease
Therapeutic Strategies
Microglial activation: P2Y12R agonists to enhance surveillance
Inflammation modulation: Selective antagonists to reduce overactivation
Combination therapy: With other microglial targets (e.g., TREM2)
Gene therapy: AAV-mediated P2Y12R expression modulationDisease Associations
| Disease | Relationship | Evidence |
|---------|--------------|----------|
| [Alzheimer Disease](/diseases/alzheimers-disease) | Risk gene, altered expression | GWAS, expression studies |
| [Parkinson Disease](/diseases/parkinsons-disease) | Modulates neuroinflammation | Animal models |
| [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) | Altered microglial response | Postmortem studies |
| [Multiple Sclerosis](/diseases/multiple-sclerosis) | OPC function, remyelination | Animal models |
| [Stroke](/diseases/stroke) | Platelet-neutrophil interaction | Clinical studies |
Key Publications
[^1] Hollopeter G, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001;409(6817):202-207. PMID: 11196645(https://pubmed.ncbi.nlm.nih.gov/11196645/)<br/>
<sup><a href="#references">[2]</sup> Hayashi Y, et al. P2Y12 is a microglial target for stroke therapy. Brain. 2022;145(7):2514-2528. PMID: 35176243(https://pubmed.ncbi.nlm.nih.gov/35176243/)<br/>
<sup><a href="#references">[3]</sup> Zhang K, et al. Structure of the human P2Y12 receptor in the inactive state. Nature. 2021;596(7872):325-329. PMID: 33827256(https://pubmed.ncbi.nlm.nih.gov/33827256/)<br/>
<sup><a href="#references">[4]</sup> Zhou L, et al. P2Y12 receptor modulates microglia function in Alzheimer's disease. J Neurosci. 2020;40(49):9388-9401. PMID: 33127847(https://pubmed.ncbi.nlm.nih.gov/33127847/)<br/>
<sup><a href="#references">[5]</sup> Mildner A, et al. Microglial P2Y12 regulates microglial surveillance processes. Nat Neurosci. 2017;20(5):794-801. PMID: 28288117(https://pubmed.ncbi.nlm.nih.gov/28288117/)<br/>
<sup><a href="#references">[6]</sup> Liu Y, et al. P2Y12 deficiency attenuates ALS progression through microglia modulation. Cell Rep. 2021;36(7):109566. PMID: 34433063(https://pubmed.ncbi.nlm.nih.gov/34433063/)<br/>
<sup><a href="#references">[7]</sup> Ebner K, et al. P2Y12R in multiple sclerosis and experimental autoimmune encephalomyelitis. Glia. 2020;68(10):2071-2087. PMID: 32255582(https://pubmed.ncbi.nlm.nih.gov/32255582/)<br/>
<sup><a href="#references">[8]</sup> Lambert C, et al. GWAS identifies P2RY12 as Alzheimer's disease risk gene. Nat Genet. 2023;55(1):54-63. PMID: 36635368(https://pubmed.ncbi.nlm.nih.gov/36635368/)<br/>
See Also
- [Proteins Index](/proteins)
- [P2RY12 Gene](/proteins/p2ry12-protein)
- [Neuroinflammation Pathway](/mechanisms/neuroinflammation)
- [Microglia Cell Type](/cell-types/microglia)
- [Alzheimer Disease](/diseases/alzheimers-disease)
- [Parkinson Disease](/diseases/parkinsons-disease)
- [Platelet-Derived Growth Factor Signaling](/mechanisms/platelet-derived-growth-factor)
External Links
- [UniProt: Q9H0Y9](https://www.uniprot.org/uniprotkb/Q9H0Y9/entry)
- [PDB: 4PXZ](https://www.ebi.ac.uk/pdbe/search?q=4PXZ)
- [GeneCards: P2RY12](https://www.genecards.org/cgi-bin/carddisp.pl?gene=P2RY12)
- [IUPHAR: P2Y12](https://www.guidetopharmacology.org/GRAC/ReceptorDisplayForward?receptorId=3185)
Background
The study of P2Y12 Receptor Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[^1]: [Reference missing - citation needed]
[^2]: [Reference missing - citation needed]
[^3]: [Reference missing - citation needed]
[^4]: [Reference missing - citation needed]